

# Kwality Pharmaceuticals Africa Limitada

Mozambique, Maputo Province, City Of Matola

## Balance Sheet As On 31st March, 2019

	Particulars	Figures as at the end of 31/03/2019
		(in Rs.)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>	
<b>1</b>	<b>Shareholders' funds</b>	
	(a) Share capital	8,867,500.00
	(b) Reserves and surplus	-23,499,216.05
	(b) Money Received against share warrents	-
<b>2</b>	<b>Share application money pending allotments</b>	-
<b>3</b>	<b>Non-current liabilities</b>	
	(a) Long-term borrowings	35,424,676.38
	(b) Deferred tax liabilities (net)	-
	(c) Other Long Term Liabilities	-
	(d) Long term provision	-
<b>4</b>	<b>Current liabilities</b>	
	(a) Short Term Borrowings	-
	<b>(b) Trade payables</b>	
	(A) total outstanding dues of micro enterprises and small enterprises	-
	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises	23,474,854.08
	(c) Other current liabilities	1,562,882.21
	(d) Short-term provisions	41,715.16
	<b>TOTAL</b>	<b>45,872,411.78</b>
<b>B</b>	<b>ASSETS</b>	
<b>1</b>	<b>Non-current assets</b>	
	(a) (i) Property, Plant and Equipment	10,576,518.30
	(ii) Intangible assets	-
	(iii) Capital Work in progress	-
	(iv) Intangible Assets under Development	
	(b) Non-current investments	
	(c) Deferred Tax Assets	-
	(d) Long term loans and Advances	
	(e) Other Non Current Assets	
<b>2</b>	<b>Current assets</b>	
	(a) Current Investments	2,126,671.62
	(b) Inventories	45,780.00
	(c) Trade receivables	20,301,096.39
	(d) Cash and cash equivalents	11,202,115.86
	(e) Short-term loans and advances	1,620,229.61
	(f) Other Current Assets	-
	<b>TOTAL</b>	<b>45,872,411.78</b>

For Kwality Pharmaceuticals Africa Limitada

Sd/-  
Ramesh Arora  
Director

Sd/-  
Rajendra Singh Golan  
Director

# Kwality Pharmaceuticals Africa Limitada

Mozambique, Maputo Province, City Of Matola

## STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH 2019

	Particulars	Figures for the year ended 31/03/2019  (in Rs.)
<b>I</b>	Revenue from operations	52,272,591.12
<b>II</b>	Other Income	486,127.50
<b>III</b>	<b>Total Income (I+II)</b>	<b>52,758,718.62</b>
<b>IV</b>	<b>Expenses</b>	
	(a) Cost of materials consumed	-
	(b) Purchase of Stock in Trade	40,850,188.40
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,011,921.53
	(d) Employee benefits expenses	1,304,498.93
	(e) Finance costs	4,417,683.64
	(f) Depreciation and amortisation expenses	618,573.75
	(g) Other expenses	4,416,801.84
	<b>Total Expenses</b>	<b>52,619,668.08</b>
<b>V</b>	<b>Profit before exceptional and extraordinary item and tax</b>	<b>139,050.54</b>
<b>VI</b>	<b>Exceptional Items</b>	-
<b>VII</b>	<b>Profit before extraordinary item and tax</b>	<b>139,050.54</b>
<b>VIII</b>	<b>Extraordinary Items</b>	-
<b>IX</b>	<b>Profit before Tax</b>	<b>139,050.54</b>
<b>X</b>	<b>Tax Expense:</b>	
	(a) Current tax expense	41,715.16
	(b) Deferred tax	-
	(c) Income tax relating to previous year	-
<b>XI</b>	<b>Profit / (Loss) for the period from continuing operations</b>	<b>97,335.38</b>
<b>XII</b>	<b>Profit / (Loss) from discontinuing operations</b>	-
<b>XIII</b>	<b>Tax from discontinuing operations</b>	-
<b>XIV</b>	<b>Profit/ (Loss) from discontinuing operations</b>	-
<b>XV</b>	<b>Profit/ (Loss) for the Period</b>	<b>97,335.38</b>

For Kwality Pharmaceuticals Africa Limitada

Sd/-  
Ramesh Arora  
Director

Sd/-  
Rajendra Singh Golan  
Director